ICML 2017 | Final results of the AIM study of ibrutinib and venetoclax in mantle cell lymphoma
Constantine Tam
• 14 Jun 2017
Constantine Tam, MBBS, MD, FRACP, FRCPA from the University of Melbourne, Melbourne, Australia gives an overview of the final results of the Phase II AIM study of ibrutinib and venetoclax in mantle cell lymphoma (MCL) patients (NCT02471391) presented at the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland. According to Prof. Tam, the results are encouraging with a complete remission rate (CRR) of 63%. Further, a vast majority of patients who are in complete remission (CR) are also minimal residual disease (MRD) negative. The results of the Phase II study have led to a global Phase III study which compares ibrutinib versus ibrutinib and venetoclax in patients with MCL (NCT03112174).
